Clinical trial
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative…
NCT00003593 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003593 |
|---|---|
| Title | Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome |
| Official title | Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms |
| Intervention type | Drug |
| Interventions | asparaginase, cytarabine, daunorubicin hydrochloride, methotrexate, therapeutic hydrocortisone, thioguanine |
| Enrollment | 254 |
| Start date | Jun 1, 1999 |
| Primary completion | Mar 1, 2007 |
| Completion | Apr 1, 2012 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 27, 2013 |
| Countries | Australia, Canada, Netherlands, New Zealand, Puerto Rico, Switzerland, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: